Veristrat
VeriStrat® is a test developed to evaluate patient prognosis and, additionally, predict benefit from cancer treatment by EGFR inhibitors. It is a serum/plasma proteomic test developed using matrix-assisted laser desorption/ionization (MALDI) mass spectrometry. VeriStrat was developed by Biodesix, Inc., a molecular diagnostics company based in Boulder, CO, USA.
The VeriStrat algorithm has been interrogated retrospectively and prospectively in samples from randomised trials, such as the PROSE study, confirming the prognostic information associated with the molecular signature. In addition, the test appeared to be predictive of erlotinib impact on survival, as only "VeriStrat Good patients" benefited from such a treatment. Additional studies have confirmed its clinical relevance.<ref name="pmid24308656">,
VeriStrat: a prognostic and/or predictive biomarker for advanced lung cancer patients?, Expert Rev Respir Med, 2014, Vol. 8(Issue: 1), pp. 1–4, DOI: 10.1586/17476348.2014.861744, PMID: 24308656,</ref>
References
<references group="" responsive="1"></references>
- Original article describing the test: http://jnci.oxfordjournals.org/content/99/11/838.full.pdf+html
- Lung Cancer Journal, “Outcome and economic implications of proteomic test-guided second- or third-line treatment for advanced non-small cell lung cancer: Extended analysis of the PROSE trial”, Hornberger et al.
- "Predictive value of a proteomic signature in patients with non-small cell lung cancer treated with second-line erlotinib or chemotherapy (PROSE): a biomarker stratified, randomised phase 3 trial," Gregorc et al. The Lancet Oncology
- A Retrospective Analysis of VeriStrat Status on Outcome of a Randomized Phase II Trial of First-Line Therapy with Gemcitabine, Erlotinib, or the Combination in Elderly Patients (Age 70 Years or Older) with Stage IIIB/IV Non-Small-Cell Lung Cancer. Stinchcombe, et al. Journal of Thoracic Oncology.
| This article is a stub. You can help WikiMD by registering to expand it. |
| This article is a stub. You can help WikiMD by registering to expand it. |
Ad. Transform your life with W8MD's Budget GLP-1 injections from $75


W8MD offers a medical weight loss program to lose weight in Philadelphia. Our physician-supervised medical weight loss provides:
- Weight loss injections in NYC (generic and brand names):
- Zepbound / Mounjaro, Wegovy / Ozempic, Saxenda
- Most insurances accepted or discounted self-pay rates. We will obtain insurance prior authorizations if needed.
- Generic GLP1 weight loss injections from $75 for the starting dose.
- Also offer prescription weight loss medications including Phentermine, Qsymia, Diethylpropion, Contrave etc.
NYC weight loss doctor appointmentsNYC weight loss doctor appointments
Start your NYC weight loss journey today at our NYC medical weight loss and Philadelphia medical weight loss clinics.
- Call 718-946-5500 to lose weight in NYC or for medical weight loss in Philadelphia 215-676-2334.
- Tags:NYC medical weight loss, Philadelphia lose weight Zepbound NYC, Budget GLP1 weight loss injections, Wegovy Philadelphia, Wegovy NYC, Philadelphia medical weight loss, Brookly weight loss and Wegovy NYC
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
